ASCLETIS-B

Ascletis Pharma opened 5.0% lower at HK$9.50 in morning session, breaking below the 20-day MA of HK$9.749 and 52.17% below its 52-week high of HK$19.86, with YTD decline of 17.53%. The company initiated global Phase III trials for oral GLP-1 obesity drug ASC30 (4,600 patients) and two Phase I US studies for obesity candidates ASC36/ASC36_35FDC, yet Q4 revenue fell 22.85% YoY to HK$526.5K while net loss widened to HK$151.2M, with persistent losses and R&D costs weighing on sentiment. However, turnover of HK$1.38M and a 0.01% turnover rate suggest limited downside from thin trading.

Ascletis Pharma opened 5.1% higher at HK$11.73 in the morning session, recouping yesterday's losses, primarily driven by the announcement of global Phase III initiation for its oral GLP-1 obesity drug ASC30, with NDA filing targeted by end-2028, boosting sentiment on its pipeline progress. The stock remains 40.9% below its 52-week high of HK$19.86 but has reclaimed both the 20-day MA (HK$9.46) and 60-day MA (HK$11.01), with a YTD gain of 1.8%. However, the latest quarterly net loss widened 66.6% YoY to HK$151 million on a 22.9% revenue decline, underscoring the gap between pipeline optimism and near-term financials.

Ascletis Pharma opened higher and rose steadily in the morning session, closing midday at HK$10.76, up 5.6% from the previous close of HK$10.19. The rally was driven by the company's announcement of a global Phase III clinical trial initiation for its oral obesity drug ASC30 (an oral small-molecule GLP-1 receptor agonist), with NDA submission expected by end of 2028, and the disclosure of positive preclinical data for its first-in-class oral small-molecule GLP-1/GIP/Amylin fixed-dose combination (FDC) that showed superior weight loss compared to tirzepatide. The company also recently repurchased shares for cancellation and scheduled a board meeting for interim results. However, despite the short-term support from MA20 (HK$9.40) crossing above MA60 (HK$11.09), the stock remains 45.8% below its 52-week high of HK$19.86, and net losses have widened YoY for two consecutive quarters (Q4 2025 net loss of HK$151.2 million, YoY loss increase of 66.6%), underscoring that fundamental improvement hinges on clinical-proof of its pipeline.

1672.HK surged 5.29% to 9.945 HKD in the morning session, recovering from the previous close of 9.445 HKD, as the company announced the initiation of a global Phase III clinical trial for oral obesity drug ASC30, targeting NDA submission by end-2028. The stock bottomed at 9.410 HKD early, then rallied to an intraday high of 9.945 HKD by 11:03 BJ, with volume of 515,010 shares and turnover of 4.99 million HKD. Despite the gain, the price remains 49.92% below the 52-week high of 19.86 HKD and below the MA60 of 11.306 HKD, though it has reclaimed the MA20 of 9.453 HKD. While Q4 2025 revenue fell 22.85% YoY to 0.527 million HKD and net loss widened 66.6% to 151.2 million HKD, the phase III catalyst and recent share repurchases for cancellation (disclosed in HKEX filings) provided positive momentum.

Ascletis Pharma surged today, closing at HK$9.5, up 5.56% on heavy volume, driven by the launch of a global Phase III study for oral obesity drug ASC30, with an NDA target by end-2028, along with positive preclinical data for ASC37 and ASC36_35. The stock opened at HK$9.03, hit an intraday high of HK$9.61 in the morning session, then eased to HK$9.365, before trading narrowly around HK$9.4 in the afternoon to close at HK$9.415, still above the morning average price of HK$9.07. However, the stock remains 52.17% below its 52-week high of HK$19.86 and below the 60-day MA of HK$11.422, with a YTD decline of 17.53%, reflecting lingering caution on pipeline execution.